Today, the New England Journal of Medicine (NEJM) published findings from the Scripps Genomic Health Initiative, a research study sponsored by Scripps Translational Science Institute (STSI) to assess the behavioral impact of personal genetic testing.
The Scripps Genomic Health Initiative provided study participants who were age 18 and older with personalized genetic risk assessments for more than 20 health conditions that may be changed by health screening and lifestyle, including diabetes, heart attack and some forms of cancer. The study was launched in 2008 and will assess changes in participants’ behaviors over a 20-year period. As a co-sponsor of the study, Navigenics provided the genetic testing used in the research.
Initial results from the Scripps Genomic Health Initiative (SGHI) are published in an article on the New England Journal of Medicine’s website, www.nejm.org. You’ll find Navigenics’ full press release on the initial findings here.
As the first major study of its kind, this research will undoubtedly influence the ongoing evolution of the personal genetic industry. Dr. Vance Vanier, CEO of Navigenics, joined SGHI researchers Drs. Eric Topol and Nicholas Schork in a webcast to discuss the research findings and implications on the industry.
You can view the webcast in the video above, and a full transcript of the webcast also follows below. Participants include:
Eric Topol, MD, PhD
Scripps Translational Science Institute, Scripps Health & The Scripps Research Institute
Author of the Scripps Genomic Health Initiative study
Nicholas Schork, PhD
Scripps Translational Science Institute & The Scripps Research Institute
Author of the Scripps Genomic Health Initiative study
Vance Vanier, MD
CEO of Navigenics
At